Mirtazapin Teva (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, leading to increased release of norepinephrine, and antagonizes 5‑HT2 and 5‑HT3 receptors while sparing 5‑HT1A. This dual action raises serotonin and norepinephrine levels in the brain, producing an antidepressant effect.

The appropriate dose of Mirtazapin Teva is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for mirtazapine during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case and discuss alternatives when appropriate.

To request Mirtazapin Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Teva (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined noradrenergic and specific serotonergic activity and strong antihistamine effect. This profile often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those who need a more activating agent.

Store Mirtazapin Teva at room temperature, below 25 °C, in the original container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Keep it out of reach of children and do not use if the packaging is damaged.

Mirtazapin Teva is taken orally, usually once daily in the evening because of its sedative effect. It can be swallowed whole with water and may be taken with or without food, unless the prescriber advises otherwise.

Serious risks include the potential for agranulocytosis or severe neutropenia, life‑threatening skin reactions such as Stevens‑Johnson syndrome, worsening depression or emergence of suicidal thoughts, severe hypotension, and rare seizures. Patients should be monitored closely for any of these events.

Mirtazapin Teva should be avoided in patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken an MAOI within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment unless dose adjustments are made under medical supervision.